Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a diabetes drug help hearts heal better after a heart attack?

NCT ID NCT07469943

Disease control Sponsor: University of Athens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether empagliflozin, a medicine used for diabetes, can help blood vessels and heart muscle recover after a heart attack. About 80 people who had a severe heart attack will either receive empagliflozin or standard care. Researchers will measure artery stiffness, blood vessel health, and heart function over 12 months to see if the drug makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
empagliflozin (a diabetes pill that also helps the heart)
What this could lead to
If it works, this could show that empagliflozin helps blood vessels and the heart recover better after a heart attack, potentially reducing future heart problems.
What could go wrong
This is a small, early-stage study with only 80 people, so results may not apply to everyone. It is not designed to prove that empagliflozin prevents death or major events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This prospective observational study will include adult patients diagnosed with acute ST-segment elevation myocardial infarction (STEMI) who are hospitalized at the Second University Cardiology Clinic of "Attikon" General Hospital. Prior to participation, all individuals will provide written informed consent in accordance with the principles outlined in the Declaration of Helsinki. A comprehensive clinical assessment will be performed for all participants, including detailed medical history, physical examination, and laboratory evaluation. Participants will be allocated into two study groups: Group A: Patients receiving empagliflozin 10 mg once daily, initiated either at hospital discharge due to the presence of type 2 diabetes mellitus, or without diabetes who exhibit reduced left ventricular ejection fraction (LVEF \<40%). Group B (Control Group): Patients who will not receive empagliflozin therapy.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * STEMI participants with type 2 diabetes or LVEF\<40% Exclusion Criteria: 1. Chronic kidney disease with estimated glomerular filtration rate (eGFR) \<60 ml/min/1.73 m² 2. Active malignancy 3. Autoimmune or autoinflammatory disorders 4. Severe hepatic impairment 5. Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabete type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myocardial infarction ST-elevation myocardial infarction type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabete type 2 Myocardial infarction (MI)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Attikon University Hospital, 2nd Department of Cardiology, National and Kapodistrina University of Athens

    RECRUITING

    Athens, Rimini1/Haidari, 12462, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.